EU Accelerated Assessment Tracker
One out of seven requests for the accelerated assessment of planned EU marketing authorization applications is known to have been granted this year to date.
You may also be interested in...
Tezepelumab was among four products that the European Medicines Agency most recently considered for review under its accelerated assessment mechanism.
New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.
Three requests for the accelerated assessment of planned EU marketing applications were considered by the European Medicines Agency last month.